|
|
|
|
|
|
|
|
|
1 The Basic Principles of GRID (Peter Goodford). |
|
|
|
|
|
1.2 Philosophy and Objectives. |
|
|
|
|
|
|
|
1.5 The GRID Force Field. |
|
|
|
|
|
1.7 Calibrating the GRID Force Field. |
|
|
|
1.8 The Output from GRID. |
|
|
|
|
|
2 Calculation and Application of Molecular Interaction Fields (Rebecca C. Wade). |
|
|
|
|
|
|
|
2.3 Selected Applications of MIFs. |
|
|
|
2.4 Concluding Remarks and Outlook. |
|
|
|
|
|
3 Protein Selectivity Studies Using GRID-MIFs (Thomas Fox). |
|
|
|
|
|
3.2 GRID Calculations and Chemometric Analysis. |
|
|
|
|
|
3.4 Discussion and Conclusion. |
|
|
|
4 FLAP: 4-Point Pharmacophore Fingerprints from GRID (Francesca Perruccio, Jonathan S. Mason, Simone Sciabola, and Massimo Baroni). |
|
|
|
|
|
|
|
|
|
4.4 Structure Based Virtual Screening (SBVS). |
|
|
|
4.5 Ligand Based Virtual Screening (LBVS). |
|
|
|
|
|
4.7 TOPP (Triplets of Pharmacophoric Points). |
|
|
|
|
|
5 The Complexity of Molecular Interaction: Molecular Shape Fingerprints by the PathFinder Approach (Iain McLay, Mike Hann, Emanuele Carosati, Gabriele Cruciani, and Massimo Baroni). |
|
|
|
|
|
|
|
5.3 The PathFinder Approach. |
|
|
|
|
|
|
|
6 Alignment-independent Descriptors from Molecular Interaction Fields (Manuel Pastor). |
|
|
|
|
6.2 GRIND. |
|
|
6.3 How to Interpret a GRIND-based 3D QSAR Model. |
|
|
|
6.4 GRIND Limitations and Problems. |
|
|
|
6.5 Recent and Future Developments. |
|
|
|
|
|
7 3D-QSAR Using the GRID/GOLPE Approach (Wolfgang Sippl). |
|
|
|
|
|
7.2 3D-QSAR Using the GRID/GOLPE Approach. |
|
|
|
7.3 GRID/GOLPE Application Examples. |
|
|
|
|
|
|
|
8 Use of MIF-based VolSurf Descriptors in Physicochemical and Pharmacokinetic Studies (Raimund Mannhold, Giuliano Berellini, Emanuele Carosati, and Paolo Benedetti). |
|
|
|
8.1 ADME Properties and Their Prediction. |
|
|
|
|
|
8.3 Application Examples. |
|
|
|
|
|
9 Molecular Interaction Fields in ADME and Safety (Giovanni Cianchetta, Yi Li, Robert Singleton, Meng Zhang, Marianne Wildgoose, David Rampe, Jiesheng Kang, and Roy J. Vaz). |
|
|
|
|
|
|
|
9.3 Role of Pgp Efflux in the Absorption. |
|
|
|
|
|
|
|
|
|
10 Progress in ADME Prediction Using GRID-Molecular Interaction Fields (Ismael Zamora, Marianne Ridderstr.m, Anna-Lena Ungell, Tommy Andersson, and Lovisa Afzelius). |
|
|
|
10.1 Introduction: ADME Field in the Drug Discovery Process. |
|
|
|
|
|
|
|
|
|
|
|
11 Rapid ADME Filters for Lead Discovery (Tudor I. Oprea, Paolo Benedetti, Giuliano Berellini, Marius Olah, Kim Fejgin, and Scott Boyer). |
|
|
|
|
|
11.2 The Rule of Five (Ro5) as ADME Filter. |
|
|
|
11.3 Molecular Interaction Fields (MIFs): VolSurf. |
|
|
|
11.4 MIF-based ADME Models. |
|
|
|
11.5 Clinical Pharmacokinetics (PK) and Toxicological (Tox) Datasets. |
|
|
|
11.6 VolSurf in Clinical PK Data Modeling. |
|
|
|
11.7 ChemGPS-VolSurf (GPSVS) in Clinical PK Property Modeling. |
|
|
|
11.8 ADME Filters: GPSVS vs. Ro5. |
|
|
|
11.9 PENGUINS: Ultrafast ADME Filter. |
|
|
|
11.10 Integrated ADME and Binding Affinity Predictions. |
|
|
|
|
|
12 GRID-Derived Molecular Interaction Fields for Predicting the Site of Metabolism in Human Cytochromes (Gabriele Cruciani, Yasmin Aristei, Riccardo Vianello, and Massimo Baroni). |
|
|
|
|
|
11.2 The Human Cytochromes P450. |
|
|
|
12.3 CYPs Characterization using GRID Molecular Interaction Fields. |
|
|
|
12.4 Description of the Method. |
|
|
|
12.5 An Overview of the Most Significant Results. |
|
|
|
|
|
|
|
|
|
|